GlassScriptPhysician profile
Dana Michele Marsh
NPI 1457910044
$726.54
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $430 · 2022: $297.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.08 | 2021-2022 | |
| Abbvie INC. | $171.98 | 2021-2022 | |
| Lilly USA, LLC | $80.53 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $66.94 | 2021-2022 | |
| Glaxosmithkline, LLC. | $63.59 | 2022 | |
| Antares Pharma, INC. | $36.00 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $27.11 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.60 | 2021 | |
| Amgen INC. | $17.49 | 2021 | |
| Astellas Pharma US INC | $16.85 | 2022 | |
| Amarin Pharma, INC. | $12.37 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Marsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.